Phase Ib dose escalation trial of SAR650984 improves outcomes in relapsed or refractory myeloma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Thomas Martin (University of California San Francisco, San Francisco, CA) discusses a phase Ib dose escalation trial of SAR650984 (anti-CD38 monoclonal antibody) in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma.

Year of Production:
Running Time:
Color/Sound:

2014
09:18
Color/Sound

Comments are closed.